Quarterly ResultMay 12, 2026, 04:07 PM
Solid Biosciences Q1 Net Loss $(56.7)M; Cash $297.1M
AI Summary
Solid Biosciences Inc. reported a net loss of $(56.7) million for the first quarter of 2026, an increase from $(39.3) million in the same period last year, driven by higher research and development expenses. The company significantly bolstered its liquidity, with cash and cash equivalents rising to $297.1 million at March 31, 2026, primarily due to a $239.9 million private placement and an $11.9 million at-the-market public offering. The company expects its current cash and available-for-sale securities of $380.7 million to fund operations for at least the next twelve months.
Key Highlights
- Net loss for Q1 2026 was $(56.7) million, compared to $(39.3) million for Q1 2025.
- Research and development expenses increased to $46.1 million in Q1 2026 from $30.9 million in Q1 2025.
- General and administrative expenses rose to $11.2 million in Q1 2026 from $9.1 million in Q1 2025.
- Cash and cash equivalents significantly increased to $297.1 million at March 31, 2026, from $59.9 million at December 31, 2025.
- Total assets grew to $422.9 million at March 31, 2026, from $232.5 million at December 31, 2025.
- Net cash used in operating activities was $(47.2) million in Q1 2026, up from $(31.9) million in Q1 2025.
- Received $239.9 million from a private placement of common stock and pre-funded warrants in March 2026.
- Received $11.9 million from an at-the-market public offering of common stock in Q1 2026.